We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Next Generation Sequencing Reveals Genetic Basis for Congenital Cataracts

By LabMedica International staff writers
Posted on 01 Sep 2014
Applying the latest high-throughput, next-generation DNA sequencing technology has enabled researchers in the United Kingdom to diagnose children with rare diseases that are characterized by the formation of congenital cataracts.

Diagnosing which of the more than 100 diseases that cause between 20,000 and 40,000 cases of congenital cataracts each year is often a lengthy, costly, and inconclusive process based on numerous clinical assessments and a detailed family history. More...


Investigators at the University of Manchester (United Kingdom) decided to modernize this process by adapting the latest high-throughput DNA sequencing technology, which is capable of simultaneously scanning for mutations in all the 115 known congenital cataracts genes.

To verify this approach, the investigators evaluated samples from 36 patients and a known positive control. They were able to determine the precise genetic cause of congenital cataracts in 75% of individuals. Among the patient group, 85% were found to have likely pathogenic mutations, all of which occurred in highly conserved domains known to be vital for normal protein function. In one case, results of DNA sequencing aided in diagnosing a patient with Warburg Micro syndrome, an extremely rare disease that is marked by an abnormally small head and the development of severe epilepsy, among other medical issues.

"There are many diseases that involve congenital cataracts but finding the exact reason was always difficult," said contributing author Dr. Graeme Black, professor of genetics and ophthalmology at the University of Manchester. "Even with a family history, diagnosing these rare diseases was always a bit of a shot in the dark."

The DNA-based test, which was described in the August 19, 2014, online edition of the journal Ophthalmology, was certified for diagnostic use by the United Kingdom's National Health Service in December 2013.

Related Links:

University of Manchester


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
New
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
Electrolyte Analyzer
BKE-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: LVOne uses blood-based biomarkers to detect stroke and identify large vessel occlusion before hospital arrival, providing objective results earlier than traditional assessments. (Photo courtesy of UpFront Diagnostics)

First-of-Its-Kind Rapid Blood Test Gains CE Mark to Support Prehospital Stroke Triage

Rapid stroke identification before hospital arrival is critical because treatment efficacy declines with every minute of delay. However, definitive assessment typically requires hospital-based imaging,... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: RealTime Labs’ Mycotoxin Extensive Panel measures 31 mold-related toxins across seven toxin classes from a single urine sample (Photo courtesy of RealTime Labs)

New Urine Test Expands Mycotoxin Analysis to 31 Markers for Broader Exposure Assessment

Clinical evaluation of mold exposure increasingly relies on urinary mycotoxin testing, but limited marker coverage and metabolite masking can make results more difficult to interpret. Broader analysis... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Collaboration combines cognitive assessment, blood testing, phlebotomy, and MRI to support faster diagnosis across the UK (Image Credt: Adobe Stock)

New UK Collaboration Expands Access to Integrated Alzheimer’s Diagnostic Testing

C2N Diagnostics and Cambridge Cognition have partnered with The Alzheimer’s Trust to create an integrated pathway aimed at supporting earlier and more accurate diagnosis of Alzheimer’s disease and related dementias.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.